These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 447017)

  • 1. Hepatic circulation and drug disposition in cirrhosis.
    Shand DG
    Gastroenterology; 1979 Jul; 77(1):185-6. PubMed ID: 447017
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug disposition in liver disease.
    Fruncillo RJ
    Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug disposition in liver disease.
    Shand DG
    N Engl J Med; 1977 Jun; 296(26):1527-8. PubMed ID: 865536
    [No Abstract]   [Full Text] [Related]  

  • 4. Clearance by the liver: current concepts in understanding the hepatic disposition of drugs.
    Larrey D; Branch RA
    Semin Liver Dis; 1983 Nov; 3(4):285-97. PubMed ID: 6359424
    [No Abstract]   [Full Text] [Related]  

  • 5. [Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].
    Nomura F; Ohnishi K; Ohto M; Takeda Y; Rikihisa T; Kanakubo Y
    Rinsho Byori; 1991 Oct; 39(10):1093-7. PubMed ID: 1762184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.
    Kawasaki S; Sugiyama Y; Iga T; Hanano M; Sanjo K; Beppu T; Idezuki Y
    Am J Gastroenterol; 1985 Oct; 80(10):801-6. PubMed ID: 4036939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prescription of drugs in liver diseases].
    Held H
    Internist (Berl); 1980 Dec; 21(12):724-34. PubMed ID: 7009474
    [No Abstract]   [Full Text] [Related]  

  • 8. A new model-independent physiological approach to study hepatic drug clearance and its applications.
    Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):577-90. PubMed ID: 6389376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis.
    Merkel C; Gatta A; Caregaro L; Sacerdoti D; Rondana M; Ruol A
    Scand J Clin Lab Invest; 1987 Nov; 47(7):667-72. PubMed ID: 2891182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver.
    Le Couteur DG; Hickey H; Harvey PJ; Gready J; McLean AJ
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1553-8. PubMed ID: 10336552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance and biologic half-life as indices of intrinsic hepatic metabolism.
    Perrier D; Gibaldi M
    J Pharmacol Exp Ther; 1974 Oct; 191(1):17-24. PubMed ID: 4423599
    [No Abstract]   [Full Text] [Related]  

  • 12. [Handling of drugs by cirrhotic patients].
    Danan G; Pariente A
    Rev Prat; 1986 Sep; 36(39):2298-308. PubMed ID: 3809928
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug dosing in chronic hepatic disease (author's transl)].
    Gugler R; Eichelbaum M
    Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misuse of the well-stirred model of hepatic drug clearance.
    Yang J; Jamei M; Yeo KR; Rostami-Hodjegan A; Tucker GT
    Drug Metab Dispos; 2007 Mar; 35(3):501-2. PubMed ID: 17325025
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug disposition and dosing in hepatic disease.
    Somogyi A; Rolan P
    Med J Aust; 1986 Sep; 145(6):284-6, 289. PubMed ID: 3747914
    [No Abstract]   [Full Text] [Related]  

  • 16. [Side effects of drugs--predictable hazards for patients with liver disease].
    Baumgarten R
    Z Arztl Fortbild (Jena); 1983; 77(9):373-5. PubMed ID: 6880279
    [No Abstract]   [Full Text] [Related]  

  • 17. [Role of clinical pharmacokinetics in the causal treatment of acute drug poisoning].
    Lesne M
    Bull Mem Acad R Med Belg; 1981; 136(8-9):443-72. PubMed ID: 7042014
    [No Abstract]   [Full Text] [Related]  

  • 18. [The metabolic clearance rate of antipyrine: a good index for the assessment of the hepatic drug-oxidizing function in cirrhotic patients (author's transl)].
    Miguet JP; Allemand H; Joanne C; Dhumeaux D
    Nouv Presse Med; 1978 Dec; 7(46):4209-11. PubMed ID: 745958
    [No Abstract]   [Full Text] [Related]  

  • 19. Binding of drugs to alpha 1-acid glycoprotein and its desialylated form. Influence on hepatic disposition and implications for drug targeting to the liver.
    Meijer DK; van der Sluijs P
    Prog Clin Biol Res; 1989; 300():143-67. PubMed ID: 2674961
    [No Abstract]   [Full Text] [Related]  

  • 20. Effective liver blood flow: determination by galactose clearance.
    Henderson JM; Hanna SS
    Can J Surg; 1983 Mar; 26(2):129-32. PubMed ID: 6824999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.